also evaluated the impact of several biomarkers (baseline levels of CgA, NSE, and multiple soluble angiogenetic biomarkers) on the OS of advanced, progressive, low- or intermediate-grade pancreatic NET patients who received everolimus or placebo in the RADIANT-3 trial. The gene discussed is ENO2; the disease is pancreatic neuroendocrine tumor.